GlassScriptPhysician profile
Willy C Tsai
NPI 1982636312
$4,266.68
in general payments reported to CMS, 2019-2025
31 companies · $898 in 2025
The $898 reported for 2025 was more than what 75% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $483 · 2020: $121 · 2021: $367 · 2022: $664 · 2023: $1,009 · 2024: $724 · 2025: $898.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,477.52 |
| Education | $153.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $574.62 | 2019-2025 | Lokelma, Farxiga, Evusheld |
| Horizon Therapeutics Plc | $426.75 | 2020-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $389.91 | 2022-2025 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $385.21 | 2019-2025 | Jynarque, Voyxact |
| Travere Therapeutics, INC. | $285.13 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $251.19 | 2021-2025 | |
| Amgen INC. | $231.22 | 2022-2025 | Krystexxa, Tavneos |
| Novartis Pharmaceuticals Corporation | $217.50 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $165.90 | 2023-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $157.46 | 2021-2024 | Veltassa |
| Alexion Pharmaceuticals, INC. | $135.35 | 2022-2024 | Soliris, Ultomiris |
| Bard Peripheral Vascular, INC. | $121.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.62 | 2023-2025 | Jardiance |
| Nxstage Medical, INC. | $99.17 | 2022 | |
| Akebia Therapeutics INC | $79.66 | 2022-2024 | Auryxia, Vafseo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $74.15 | 2021-2023 | Benlysta |
| Xeris Pharmaceuticals, INC. | $72.59 | 2025 | Keveyis |
| Baxter Healthcare | $62.50 | 2019 | |
| Genentech, INC. | $53.45 | 2025 | |
| Aurinia Pharma U.S., INC. | $51.39 | 2022-2023 | Lupkynis |
| Fresenius USA Marketing, INC. | $50.41 | 2022-2024 | Velphoro |
| Mallinckrodt Enterprises LLC | $48.52 | 2019 | |
| Ardelyx, INC. | $44.03 | 2024 | Ibsrela |
| Ani Pharmaceuticals, INC. | $34.97 | 2022-2023 | Purified Cortrophin Gel |
| Opko Pharmaceuticals, LLC | $27.65 | 2019-2021 | |
| Rockwell Medical, INC. | $23.77 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $23.10 | 2021 | |
| Apellis Pharmaceuticals, INC. | $22.91 | 2025 | Empaveli |
| Novo Nordisk INC | $20.76 | 2024 | Ozempic, Rybelsus |
| Scpharmaceuticals INC. | $16.91 | 2025 | |
| Lilly USA, LLC | $16.42 | 2024 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willy Tsai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.